DGDA Bangladesh Medical Device Registration

Medical devices and in vitro diagnostics in Bangladesh are overseen by the Directorate General of Drug Administration (DGDA) under the Ministry of Health and Family Welfare. DGDA manages product registration, establishment activities, import controls, inspections, and post-market enforcement. Because forms and implementation practice can change, applicants should confirm the current process through the official DGDA website.

Bangladesh medical device classification

Bangladesh uses a risk-based medical device framework. The product's intended use, invasiveness, duration of contact, active functions, and possible harm if it fails influence its class and the evidence expected. IVDs require their own risk analysis, particularly where an incorrect result could create an individual or public-health risk. A written classification rationale should be completed before preparing the dossier or estimating timelines.

Local applicant and establishment readiness

A manufacturer without a Bangladesh legal entity generally appoints a locally licensed importer or authorized representative to interact with DGDA and support importation. The local entity's establishment permissions and the manufacturer's authorization should be in place before the product filing. The commercial agreement should address ownership and access to the dossier, renewal responsibilities, regulatory changes, complaint escalation, adverse-event reporting, recalls, and the transfer of registrations if representation changes.

Registration evidence

The exact file depends on risk and product type, but commonly includes administrative forms, manufacturer and site details, quality-management-system evidence such as ISO 13485, intended use, classification rationale, device descriptions, labeling and instructions for use, authorization letters, reference-market approvals or free-sale evidence where applicable, and test, clinical, or performance evidence proportionate to the claims. Translations and locally required labels must remain consistent with the approved product.

Applicants should allow time for document questions, legalized or authenticated records where requested, import permissions, and any samples or testing required for the route. A certificate or approval in another market can support the evidence package but does not replace a Bangladesh-specific assessment.

Lifecycle compliance

Before commercial shipment, verify the current registration, approved models and sites, local establishment license, labeling, and import documents. Manufacturers and local partners need working procedures for complaints, distribution records, vigilance, field safety corrective actions, and recalls. Design, intended-use, manufacturing-site, software, labeling, or quality-system changes should be assessed for DGDA notification or approval before implementation.

Bangladesh pathway and evidence decisions

DGDA’s published registration guidance and current imported-device checklist should be read together. Verify the actual certificate term and current application instructions; do not assume that every Class A record is perpetual or every product receives a decision within one fixed quarterly cycle. Prepare the full file before committing to a launch date.

Use the official DGDA instructions for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.

For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.